YMAB - Y-mAbs Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.71
DETAILS
HIGH:
$24.00
LOW:
$8.60
MEDIAN:
$8.60
CONSENSUS:
$12.71
UPSIDE:
47.62%
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Revenue | 87.7 | 84.8 | 65.3 | 34.9 | 20.8 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15.3 | 11.4 | 7.6 | 2.5 | 2.2 | 0.2 | 0.0 | 0 | 0 |
| Gross Profit | 72.4 | 73.4 | 57.7 | 32.4 | 18.5 | (0.2) | (0.0) | 0 | 0 |
| Operating Expenses | |||||||||
| R&D Expenses | 49.0 | 54.2 | 91.6 | 93.2 | 93.7 | 63.5 | 34.3 | 14.3 | 13.9 |
| SG&A Expenses | 54.6 | 44.9 | 60.9 | 54.6 | 44.8 | 19.5 | 9.0 | 4.9 | 3.2 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 | (0.0) | 0.1 | (0.0) |
| Operating Expenses | 103.6 | 99.1 | 152.5 | 147.8 | 138.5 | 83.0 | 43.2 | 19.2 | 17.0 |
| Operating Income | |||||||||
| Operating Income | (31.2) | (25.7) | (94.8) | (115.4) | (119.9) | (83.0) | (43.2) | (19.2) | (17.0) |
| Interest Expense | 0 | 0 | 0.8 | 1.9 | 0 | 2.0 | 0 | 0 | 0 |
| Interest Income | 1.4 | 4.8 | 0 | 0 | 0.6 | 2.0 | 0 | 0 | 0 |
| Profitability | |||||||||
| EBITDA | (30.7) | (24.9) | (94.7) | (54.5) | (119.5) | (82.8) | (43.2) | 0.1 | (0.0) |
| EBIT | (31.2) | (25.7) | (95.6) | (55.3) | (119.9) | (83.0) | (43.3) | (19.2) | (17.1) |
| Income Before Tax | (29.8) | (20.9) | (95.6) | (55.3) | (119.3) | (81.0) | (43.3) | (19.2) | (17.1) |
| Income Tax Expense | (0.1) | 0.6 | 0 | 0 | 0 | 0 | (0.0) | 0 | 0 |
| Net Income | (29.7) | (21.4) | (95.6) | (55.3) | (119.3) | (78.9) | (43.3) | (19.2) | (17.1) |
| Per Share Data | |||||||||
| EPS (Basic) | -0.67 | -0.49 | -2.20 | -1.28 | -2.97 | -2.24 | -1.50 | -0.58 | -0.97 |
| EPS (Diluted) | -0.67 | -0.49 | -2.20 | -1.28 | -2.97 | -2.24 | -1.50 | -0.58 | -0.97 |
| Shares Outstanding | 44.3 | 43.6 | 43.7 | 43.2 | 40.1 | 35.2 | 28.8 | 33.3 | 17.6 |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Current Assets | |||||||||
| Cash & Cash Equivalents | 67.2 | 78.6 | 105.8 | 181.6 | 114.6 | 207.1 | 147.8 | 90.5 | 16.9 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 19.7 | 22.5 | 12.5 | 7.7 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 7.2 | 5.1 | 6.7 | 5.5 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.4 | 5.0 | 5.5 | 7.5 | 7.7 | 4.8 | 3.7 | 0.9 | 0.4 |
| Total Current Assets | 98.5 | 111.1 | 130.4 | 202.3 | 122.4 | 212.0 | 151.5 | 91.4 | 17.3 |
| Non-Current Assets | |||||||||
| Property, Plant & Equipment | 0.9 | 1.6 | 2.3 | 5.7 | 6.4 | 4.0 | 0.2 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.3 | 2.6 | 3.0 | 1.7 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 18.3 | 12.5 | 5.7 | 3.2 | 3.3 | 0.4 | 0.2 | 0.8 | 0 |
| Total Non-Current Assets | 21.4 | 16.8 | 11.0 | 10.5 | 9.7 | 4.4 | 0.4 | 0.8 | 0 |
| Total Assets | 119.9 | 127.9 | 141.5 | 212.8 | 132.0 | 216.4 | 151.9 | 92.1 | 17.3 |
| Current Liabilities | |||||||||
| Account Payables | 6.7 | 6.1 | 14.2 | 13.6 | 9.4 | 8.5 | 5.9 | 5.9 | 2.2 |
| Short-Term Debt | 0 | 0.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.4 | 8.4 | 2.4 | 5.7 | 3.6 | 0.4 | 0 | 0 | 0 |
| Total Current Liabilities | 23.7 | 20.1 | 28.3 | 27.9 | 19.5 | 13.6 | 9.1 | 7.9 | 3.0 |
| Non-Current Liabilities | |||||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.0 | 6.2 | 3.1 | 3.0 | 4.7 | 2.2 | 2.3 | 2.0 | 2.2 |
| Total Non-Current Liabilities | 4.2 | 6.8 | 4.0 | 4.8 | 6.7 | 3.9 | 2.3 | 2.0 | 2.2 |
| Total Liabilities | 27.9 | 26.9 | 32.2 | 32.7 | 26.2 | 17.5 | 11.4 | 10.0 | 5.2 |
| Stockholders' Equity | |||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (487.1) | (457.5) | (436.0) | (340.5) | (285.2) | (165.9) | (84.8) | (41.6) | (22.4) |
| Accumulated Other Comprehensive Income | 2.3 | 0.4 | 1.3 | 1.4 | (0.5) | 0.1 | 0.0 | (0.2) | 0.0 |
| Total Stockholders' Equity | 92.0 | 101.0 | 109.2 | 180.1 | 105.8 | 198.9 | 140.5 | 82.2 | 12.1 |
| Total Liabilities & Equity | 119.9 | 127.9 | 141.5 | 212.8 | 132.0 | 216.4 | 151.9 | 92.1 | 17.3 |
| Debt Metrics | |||||||||
| Total Debt | 0.8 | 1.4 | 1.8 | 3.6 | 4.0 | 2.2 | 0 | 0 | 0 |
| Net Debt | (66.4) | (77.2) | (104.0) | (177.9) | (110.7) | (204.9) | (147.8) | (90.5) | (16.9) |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | (29.7) | (21.4) | (95.6) | (55.3) | (119.3) | (81.0) | (43.3) | (19.2) | (17.1) |
| Depreciation & Amortization | 0.5 | 0.7 | 0.8 | 0.8 | 0.4 | 0.2 | 0.0 | 0 | 0 |
| Stock-Based Compensation | 14.6 | 14.5 | 25.6 | 19.3 | 16.1 | 4.7 | 2.0 | 0.6 | 0.3 |
| Change in Working Capital | (3.6) | (19.7) | (10.4) | (7.3) | 3.4 | 2.7 | (0.0) | 2.7 | 3.4 |
| Other Non-Cash Items | 2.5 | (1.3) | 3.6 | (62.0) | 8.7 | 0.0 | 0.1 | (0.1) | 2.3 |
| Operating Cash Flow | (15.7) | (27.2) | (75.9) | (102.6) | (91.2) | (73.5) | (41.2) | (15.9) | (11.2) |
| Investing Activities | |||||||||
| Capital Expenditure | 0 | 0 | 0 | (1.0) | (0.2) | (2.0) | (0.2) | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 62.0 | (2.6) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 61.0 | (2.8) | (2.0) | (0.2) | 0 | 0 |
| Financing Activities | |||||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0.4) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0.6 | 0 | 0 | (1.0) | (0.3) | 0 |
| Financing Cash Flow | 4.3 | 0.1 | 0.1 | 108.3 | 2.0 | 134.7 | 98.8 | 89.6 | 19.0 |
| Cash Position | |||||||||
| Net Change in Cash | (11.4) | (27.1) | (75.8) | 66.9 | (92.5) | 59.3 | 57.4 | 73.6 | 7.8 |
| Cash at Beginning | 78.6 | 105.8 | 181.6 | 114.6 | 207.1 | 147.9 | 90.5 | 16.9 | 9.1 |
| Cash at End | 67.2 | 78.6 | 105.8 | 181.6 | 114.6 | 207.1 | 147.9 | 90.5 | 16.9 |
| Free Cash Flow | (15.7) | (27.2) | (75.9) | (103.5) | (91.4) | (75.5) | (41.5) | (15.9) | (11.2) |
| Key Metrics | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 87.7 | 84.8 | 65.3 | 34.9 | 20.8 | 0 | 0 | 0 | 0 |
| Gross Profit | 72.4 | 73.4 | 57.7 | 32.4 | 18.5 | (0.2) | (0.0) | 0 | 0 |
| Operating Income | (31.2) | (25.7) | (94.8) | (115.4) | (119.9) | (83.0) | (43.2) | (19.2) | (17.0) |
| Net Income | (29.7) | (21.4) | (95.6) | (55.3) | (119.3) | (78.9) | (43.3) | (19.2) | (17.1) |
| EPS (Diluted) | -0.67 | -0.49 | -2.20 | -1.28 | -2.97 | -2.24 | -1.50 | -0.58 | -0.97 |
| Balance Sheet | |||||||||
| Cash & Equivalents | 67.2 | 78.6 | 105.8 | 181.6 | 114.6 | 207.1 | 147.8 | 90.5 | 16.9 |
| Total Assets | 119.9 | 127.9 | 141.5 | 212.8 | 132.0 | 216.4 | 151.9 | 92.1 | 17.3 |
| Total Debt | 0.8 | 1.4 | 1.8 | 3.6 | 4.0 | 2.2 | 0 | 0 | 0 |
| Stockholders' Equity | 92.0 | 101.0 | 109.2 | 180.1 | 105.8 | 198.9 | 140.5 | 82.2 | 12.1 |
| Cash Flow | |||||||||
| Operating Cash Flow | (15.7) | (27.2) | (75.9) | (102.6) | (91.2) | (73.5) | (41.2) | (15.9) | (11.2) |
| Capital Expenditure | 0 | 0 | 0 | (1.0) | (0.2) | (2.0) | (0.2) | 0 | 0 |
| Free Cash Flow | (15.7) | (27.2) | (75.9) | (103.5) | (91.4) | (75.5) | (41.5) | (15.9) | (11.2) |